Welcome to our dedicated page for CERUS SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
CERUS CORP President and CEO William Mariner Greenman reported an open-market sale of 447,757 shares of common stock on March 12, 2026 at a weighted average price of $1.6572 per share. The footnotes state the instruction was intended to comply with Rule 10b5-1 and was elected on the grant date to cover statutory tax withholding obligations and brokerage fees tied to the vesting of restricted stock units, so it was not a discretionary sale. After this transaction, he directly owned 4,998,493 shares of Cerus common stock.
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an open-market sale of 127,544 shares of Common Stock at a weighted average price of $1.6572 per share. According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1.
The filing explains the sale was elected on the date of grant to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of certain restricted stock units, and is not a discretionary sale by the CFO. After this transaction, he directly holds 1,040,551 shares of Cerus common stock.
CERUS CORP Chief Medical Officer Benjamin Richard J reported an open-market sale of 101,740 shares of Common Stock at a weighted average price of $1.6572 per share. After this transaction, he directly holds 777,361 shares.
According to the footnotes, these shares were sold under an instruction intended to comply with Rule 10b5-1 that was elected on the grant date to cover statutory tax withholding obligations and related brokerage fees tied to the vesting of restricted stock units, and are described as not a discretionary sale. The sales occurred in multiple trades at prices ranging from $1.62 to $1.73 per share.
Cerus Corporation has appointed Vivek Jayaraman, currently Chief Operating Officer, as its next President and Chief Executive Officer effective July 1, 2026. On that date, current CEO and Board Chair William “Obi” Greenman will transition to the role of Executive Chairman, and Jayaraman will join the Board.
Under a new letter agreement effective March 11, 2026, Jayaraman will receive an annual base salary of $740,000, a target annual bonus opportunity of up to 80% of base salary starting in 2027, and will be eligible for equity incentives. These include a promotion equity award with a target value of $2,000,000 (75% time-based and 25% performance-based restricted stock units) and a one-time promotional performance-based award with a target value of $1,000,000. The number of shares for these awards will be based on the 30-day average closing price of Cerus common stock, but not less than $2.50 per share for calculation purposes.
If Jayaraman is terminated without cause or resigns for good reason, he may receive 12 months of base salary, a prorated annual bonus in certain cases, up to 12 months of COBRA premium support or equivalent cash payments, and full vesting of unvested time-based and performance-based restricted stock units, including in connection with a qualifying change in control.
CERUS CORP’s Chief Medical Officer Benjamin Richard J reported a mix of stock awards and planned sales. On March 5, 2026, he acquired 55,220 shares of common stock as a grant or award at no cost, increasing his direct holdings.
He then reported selling a total of 125,894 common shares in open-market transactions on March 5, 6, and 9, 2026 at weighted average prices of about $2.06, $2.01, and $1.88 per share. Footnotes state these sales were made under a Rule 10b5-1 trading plan and instructions elected on the grant date to cover statutory tax withholding and related fees, and are described as non-discretionary. After these transactions, he directly owns 879,101 Cerus common shares.
Cerus Corp’s chief financial officer Kevin Dennis Green reported a mix of stock awards and sales. On March 5, 2026, he acquired 63,854 shares of common stock in a grant or award at $0.00 per share, increasing his direct holdings.
On March 5 and 6, 2026, he sold a total of 83,021 shares of common stock in open‑market transactions at weighted average prices of about $2.06 and $2.01 per share. The filing notes that some sales were made under a Rule 10b5‑1 trading plan and that certain shares were sold pursuant to instructions elected at grant solely to cover statutory tax withholding and related brokerage fees, described as not discretionary sales.
After these transactions, Green directly owned 1,168,095 shares of Cerus common stock.
Cerus Corp Chief Medical Officer Benjamin Richard reported multiple stock transactions in early March 2026. He received a grant or award of 55,220 shares of common stock on March 5, 2026, at no stated purchase price. Around the same time, he completed open-market sales totaling 125,894 shares at weighted average prices between about $1.88 and $2.06 per share, including block and multiple-price trades. A portion of the shares sold was under a pre-set Rule 10b5-1 instruction to cover tax withholding and related fees on vesting restricted stock units, described as non-discretionary. After these transactions, he directly owned 879,101 common shares.
Cerus Corp Chief Legal Officer Chrystal Jensen reported two stock transactions. On March 5, 2026, Jensen acquired 55,220 shares of common stock as a grant or award at $0.00 per share, bringing direct holdings to 1,083,514 shares. On March 6, 2026, Jensen sold 30,845 shares of common stock at a weighted average price of $2.0055 per share, leaving 1,059,139 shares directly owned. The sale was executed under a Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees related to vesting restricted stock units and was not a discretionary sale.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported both a stock grant and a tax-related sale of common shares. On March 5, 2026, he acquired 80,320 shares of common stock as a grant or award, increasing his direct holdings to 1,946,968 shares.
On March 6, 2026, he executed an open-market Rule 10b5-1 sale of 34,094 shares at a weighted average price of $2.0055 per share to cover statutory tax withholding obligations and related brokerage fees, a non-discretionary transaction that left him with 1,912,874 directly held shares.
CERUS CORP President and CEO William Mariner Greenman reported offsetting stock transactions. On March 5, 2026, he acquired 193,270 shares of common stock as a grant at $0.0000 per share. On March 6, 2026, he sold 78,187 shares at a weighted average price of $2.0055 per share pursuant to a Rule 10b5-1 instruction to cover statutory tax withholding and related brokerage fees. Following these transactions, he held 5,446,250 shares directly.